WO2017051585A1 - 吸入香料、香水、及び食品香料 - Google Patents
吸入香料、香水、及び食品香料 Download PDFInfo
- Publication number
- WO2017051585A1 WO2017051585A1 PCT/JP2016/069931 JP2016069931W WO2017051585A1 WO 2017051585 A1 WO2017051585 A1 WO 2017051585A1 JP 2016069931 W JP2016069931 W JP 2016069931W WO 2017051585 A1 WO2017051585 A1 WO 2017051585A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fragrance
- inhalation
- mass
- amount
- inhaled
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/40—Tea flavour; Tea oil; Flavouring of tea or tea extract
- A23F3/42—Isolation or recuperation of tea flavour or tea oil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q13/00—Formulations or additives for perfume preparations
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
Definitions
- the present invention relates to an inhalation fragrance exhibiting an antioxidant action.
- Patent Document 2 when green tea extract is used as a fragrance, it is known to have a mental sedative effect (for example, Patent Document 2).
- JP 2004-2237 A Japanese Patent No. 5306160
- the problem to be solved by the present invention is to provide an inhalation fragrance that can be taken regardless of oral administration.
- the inhalation fragrance according to the present invention is a liquid inhalation fragrance, which contains green leaf alcohol and linalool, and uses ethanol as a main solvent.
- FIG. 1 The figure which shows the quantity of 8-OHdG in the urine accompanying the aging in Experiment 1.
- FIG. The figure which shows the quantity of 8-OHdG in the urine accompanying the irradiation in Experiment 2.
- FIG. The figure which shows the time-dependent change of the amount of drinking in Experiment 3.
- FIG. The figure which shows the quantity of 8-OHdG in the urine accompanying the aging in Experiment 4
- the figure which shows the quantity of 8-OHdG in the urine accompanying the irradiation in Experiment 5 The figure which shows the measurement result of the antioxidant ability in the blood serum in Experiment 6.
- FIG. 6 The figure which shows the measurement result of the antioxidant ability in the blood serum in Experiment 6.
- the inhalation fragrance of this embodiment contains green leaf alcohol and linalool as active ingredients. Further, the inhaled fragrance may further contain other active ingredients such as benzyl alcohol and impurities.
- the inhaled fragrance is liquid at room temperature (18 ° C. to 25 ° C.).
- the main solvent of the inhaled fragrance can be ethanol. Accordingly, when inhaled perfume is heated to a temperature around 35 ° C. to 37 ° C., which is about the body temperature of humans, green leaves alcohol and linalool, which are active ingredients, volatilize and can be inhaled by humans and animals. Moreover, the inhaled fragrance gradually evaporates even at room temperature, and can be inhaled by humans and animals.
- Aoba alcohol is another name for cis-3-hexen-1-ol, which is called hexenol and is a substance contained in tea leaves. Green leaf alcohol may contain an isomer. Ethanol is a good solvent for green leaf alcohol.
- Linalool refers to 3,7-dimethyl-1,6-octadien-3-ol and is a substance contained in tea leaves. Ethanol is a good solvent for linalool.
- green leaf alcohol is contained in an amount of 0.02% by mass to 0.5% by mass and linalool is contained in an amount of 0.005% by mass to 0.1% by mass with respect to the total amount.
- the balance can be ethanol and water. In this case, for example, ethanol can be 99.9% by mass and water can be the balance.
- the inhaled fragrance contains impurities, other fragrances, surfactants, coloring agents, etc., the effect of the inhaled fragrance is not lost.
- the contaminants mean those that have little influence on the effect of the inhaled fragrance even if included in the inhaled fragrance. Some contaminants may be desirable in inhalation fragrances.
- the inhalation fragrance having the above composition has a fragrance, and has an antioxidant effect when inhaled by humans and animals.
- the antioxidant action includes an antioxidant action against oxidation due to aging and an antioxidant action against radiation stress.
- Aoba alcohol which is one of the active ingredients of inhaled fragrances, has conventionally been discarded as steam in the stage of tea making. Therefore, green tea alcohol is hardly contained in tea products such as Sencha.
- flavor of this embodiment can be manufactured by collect
- the inhaled fragrance can be used as it is or as a perfume containing other fragrances, surfactants and coloring agents. Even if this perfume contains other fragrances, various solvents, surfactants, coloring agents, etc., it does not lose the above-mentioned antioxidant action and antipsychotic stress action.
- ⁇ Inhalation fragrance may contain other active ingredients.
- Other active ingredients include benzyl alcohol, methyl salicylate, geraniol, 2-phenylethanol, ⁇ -ionone, (E) -nerolidol, indole and the like. These other active ingredients enhance the antioxidant and antipsychotic stress effects of green leaf alcohol and linalool.
- the preferable mixing ratio is 0.001% by mass or more and 0.05% by mass or less with respect to the total amount of the inhaled fragrance.
- the inhaled fragrance can be used as it is, or as it is, or as a food fragrance containing a surfactant and a coloring agent.
- a surfactant and a coloring agent for example, sprinkling inhalation fragrance on powdered tea and pouring hot water can make a fragrant tea.
- the components of the inhaled fragrance are ingested by inhalation and exhibit an antioxidant effect and an antipsychotic stress effect.
- the definition of “oxidative stress” by the Japanese Antioxidant Society is “the difference between the oxidative damage potential of the active oxygen group generated in vivo and the antioxidant potential of the in vivo antioxidant system”.
- the state where “oxidation stress” is present is a state where an excessive active oxygen group that cannot be captured by the in-vivo antioxidant system is generated.
- flavor of this embodiment is shown by the experiment 1 and experiment 2 which are shown below that there exists an effect
- flavor of this embodiment has an antioxidant effect not only to oxidative stress by aging or radiation, but also to oxidative stress by other causes, such as air pollution and tobacco.
- inhalation fragrance is described in detail in Japanese Patent Application Laid-Open No. 2015-109832 relating to the applicant's patent application.
- fresh tea leaves are steamed with steam at about 100 ° C. for 30 to 120 seconds.
- This steam is collected and cooled to about 40 ° C. to 60 ° C. to liquefy to obtain a stock solution.
- This stock solution is extracted with hexane, and a liquid inhalation fragrance is obtained at room temperature (18 ° C. to 25 ° C.) having the above composition using ethanol as a solvent.
- Aoba alcohol 0.5% by mass Linalool: 0.1% by mass Benzyl alcohol: 0.001% by mass Ethanol: 99.2% by mass Other active ingredients: 0.1% by mass Other active ingredients include methyl salicylate, geraniol, 2-phenylethanol, ⁇ -ionone, (E) -nerolidol, and indole in appropriate amounts. Contaminants: 0.05% by mass The main impurities include 1-penten-3-ol, heptanal, (Z) -3-hexanol, octanol. Water: the rest
- FIG. 1 is an external view of the metabolic cage 1.
- a water feeder 13 and a feeder 14 are connected to a main chamber 12 in which a mouse is placed.
- a net 15 is stretched in the main room 12 and a mouse is placed on the net 15.
- an excrement container 16 for separating and accumulating feces and urine. All experiments were performed at room temperature.
- the lid 11 is installed in the main room.
- the lid portion 11 has a plurality of intake holes.
- a non-woven fabric is disposed at a portion corresponding to the intake hole.
- the inhalation fragrance was dropped on the nonwoven fabric to expose the mouse, and the inhalation fragrance was ingested by spontaneous breathing.
- 8-OHdG (8-hydroxy-2'-deoxyguanosine) is a DNA oxidative damage marker and is often measured when measuring oxidative stress due to active oxygen. The greater the oxidative stress, the more 8-OHdG in the urine. In this experiment, urinary 8-OHdG was measured as follows.
- FIG. 2 is a graph showing the amount of 8-OHdG in urine accompanying aging in Experiment 2 (the amount of 8-OHdG (ng) relative to 1 mg of creatinine).
- the horizontal axis represents time, and the vertical axis represents the amount of 8-OHdG.
- the amount of 8-OHdG in urine increased with aging in both the control indicated by ⁇ and the administration group indicated by ⁇ .
- the rate of increase in the administration group was clearly lower than the control, with a significant difference of less than 5% risk.
- mice were divided into the following groups, and comparative experiments were performed.
- Group 1 Control (does not administer inhalation fragrance and does not receive radiation)
- Second group The control is irradiated with 0.5 Gy of radiation only once.
- Group 3 Inhalation fragrance is administered and no radiation is applied.
- Group 4 Inhalation fragrance is administered and 0.5 Gy of radiation is irradiated only once.
- 200 ⁇ l of inhalation fragrance was dropped on a non-woven fabric installed on the lid 11 and administered by natural inhalation every day. The control received no inhalation fragrance.
- Radiation was performed by whole body irradiation of 0.5 Gy using an X-ray irradiation apparatus (manufactured by Hitachi Engineering & Service, MBR-1520) at an irradiation dose rate of 0.68 Gy / min.
- FIG. 3 is a graph showing the amount of 8-OHdG in urine accompanying irradiation with radiation in Experiment 2 (the amount of 8-OHdG (ng) relative to 1 mg of creatinine).
- the horizontal axis represents time, and the vertical axis represents the amount of 8-OHdG.
- the amount of 8-OHdG in urine increased with time in both the second group and the fourth group irradiated with radiation.
- the amount of 8-OHdG in the urine of group 2 was clearly increased with a significant difference of less than 5% of the risk of group 1 after week 1 and after week 7.
- the amount of 8-OHdG in the urine of the fourth group was not significantly different from that of the third group when administered for 1 week and when administered for 7 weeks.
- Example 3 Verification of antipsychotic stress action Five ICR mice were divided into control and administration groups. In the administration group, 200 ⁇ l of inhalation fragrance was dropped on a non-woven fabric installed on the lid 11 and administered by natural inhalation every day. The control received no inhalation fragrance. And the time-dependent change of the amount of drinking water was compared about each group.
- FIG. 4 is a diagram showing the change over time in the amount of water consumed in Experiment 3. As shown in FIG. 4, in the first to third weeks after the start of administration, the amount of water consumed in the administration group was significantly less than the control due to a risk rate of less than 5%.
- Example 4 Additional test of verification of antioxidant action against oxidation due to aging
- Five ICR mice were divided into control and administration groups.
- 1 ml of inhalation fragrance diluted 5 times with water is sprayed on the floor of the breeding cage in which the mice of the administration group are housed daily until the third week and then three times a week, and then inhaled by spontaneous breathing.
- a fragrance was ingested.
- 1 ml of water was sprayed every day until the third week and then three times a week on the floor of a breeding cage in which the control mice were housed.
- the amount of 8-OHdG in the urine per day was measured in the same procedure as in Experiment 1.
- FIG. 5 is a view showing the amount of 8-OHdG in urine accompanying aging in Experiment 4 (the amount of 8-OHdG (ng) relative to 1 mg of creatinine).
- the horizontal axis represents time, and the vertical axis represents the amount of 8-OHdG.
- the control tends to increase the amount of 8-OHdG in the urine as it ages, but the administration group to which inhaled fragrance was administered does not show an increase in the amount of 8-OHdG in the urine.
- the administration group had a risk rate of less than 5% and a significantly lower amount of 8-OHdG in the urine than the control.
- FIG. 6 is a view showing the amount of 8-OHdG in urine accompanying irradiation with radiation in Experiment 5 (the amount of 8-OHdG (ng) relative to 1 mg of creatinine).
- the horizontal axis represents the radiation dose, and the vertical axis represents the amount of 8-OHdG.
- the method for measuring 8-OHdG is the same as in Experiment 1.
- antioxidant capacity in serum was measured.
- Antioxidant ability in serum was measured using “PAO-U” manufactured by Japan Aging Control Laboratory.
- FIG. 7 is a diagram showing the measurement results of antioxidant capacity in serum in Experiment 6.
- the vertical axis represents the measurement result of “PAO-U”.
- the antioxidant capacity of the control and the antioxidant capacity of the administration group were compared, the antioxidant capacity of the administration group was significantly increased at a risk rate of less than 5% relative to the control.
- the irradiation group was irradiated with radiation, the antioxidant capacity was significantly reduced at a risk rate of less than 5%.
- inhaled fragrances have an antioxidant action against oxidation due to aging and an antioxidant action against radiation stress when inhaled. Further, it was found that the inhaled fragrance is effective even if it contains impurities and other fragrances. Furthermore, it was found that when inhaled fragrance is inhaled, it has antipsychotic stress action.
- flavor of this embodiment contains green leaf alcohol and linalool as an active ingredient, and uses ethanol as a main solvent. Therefore, it becomes easy to take inhaled fragrance by inhalation, and by taking inhalation, it exhibits an antioxidant action against oxidation due to aging and an antioxidant action against radiation stress. In addition, by taking inhaled fragrances by inhalation, a high antipsychotic stress action can be obtained.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Tea And Coffee (AREA)
- Seasonings (AREA)
Abstract
Description
吸入香料は、出願人の特許出願にかかる特開2015-109832に詳説されている。概要を説明すると、生茶葉を約100℃の蒸気により30~120秒蒸す。この蒸し蒸気を回収し、40℃~60℃程度に冷却して液化し、原液とする。この原液をヘキサンによって抽出し、エタノールを溶媒として上記組成の常温(18℃~25℃)において液体の吸入香料を得る。
(処方例1)
青葉アルコール :0.02質量%
リナロール :0.005質量%
エタノール :99.9質量%
水 :残部
青葉アルコール :0.2質量%
リナロール :0.03質量%
エタノール :99.9質量%
水 :残部
青葉アルコール :0.5質量%
リナロール :0.1質量%
ベンジルアルコール:0.001質量%
エタノール :99.2質量%
その他の有効成分 :0.1質量%
その他の有効成分は、サリチル酸メチル、ゲラニオール、2フェニルエタノール、β-イオノン、(E)-ネロリドール、インドールを適量ずつ含む。
夾雑物 :0.05質量%
主な夾雑物は、1-ペンテン-3-オール、ヘプタナール、(Z)-3-ヘキサノール、オクタノールを含む。
水 :残部
青葉アルコール :0.5質量%
リナロール :0.05質量%
ベンジルアルコール:0.05質量%
エタノール :99.2質量%
その他の有効成分 :0.1質量%
その他の有効成分は、サリチル酸メチル、ゲラニオール、2フェニルエタノール、β-イオノン、(E)-ネロリドール、インドールを適量ずつ含む。
夾雑物 :0.05質量%
主な夾雑物は、1-ペンテン-3-オール、ヘプタナール、(Z)-3-ヘキサノール、オクタノールを含む。
水 :残部
青葉アルコール :0.5質量%
リナロール :0.05質量%
ベンジルアルコール:0.05質量%
エタノール :97.1質量%
その他の有効成分 :0.1質量%
その他の有効成分は、サリチル酸メチル、ゲラニオール、2フェニルエタノール、β-イオノン、(E)-ネロリドール、インドールを適量ずつ含む。
夾雑物 :0.05質量%
主な夾雑物は、1-ペンテン-3-オール、ヘプタナール、(Z)-3-ヘキサノール、オクタノールを含む。
リモネン :0.2重量%(他の香料として)
界面活性剤 :1.8重量%
着色料 :適量
水 :残部
青葉アルコール :0.5質量%
リナロール :0.05質量%
ベンジルアルコール:0.05質量%
エタノール :98質量%
その他の有効成分 :0.1質量%
その他の有効成分は、サリチル酸メチル、ゲラニオール、2フェニルエタノール、β-イオノン、(E)-ネロリドール、インドールを適量ずつ含む。
夾雑物 :0.05質量%
主な夾雑物は、1-ペンテン-3-オール、ヘプタナール、(Z)-3-ヘキサノール、オクタノールを含む。
界面活性剤 :1質量%
着色料 :適量
水 :残部
ICRマウスの雌10匹を1匹ずつ代謝ケージ1に入れ、5匹をコントロール(対照群)、5匹を投与群とした。図1は、代謝ケージ1の外観図である。図1に示すように、代謝ケージ1は、マウスを入れる主室12に給水器13、給餌器14が接続される。主室12には網15が張られ、網15の上にマウスが入れられる。網15の下方には糞と尿を分離して蓄積する排泄物容器16が接続される。実験はすべて常温において行われた。
新生マウスの生後2週目まで毎日吸入香料20μlを、2週目以降は毎日吸入香料200μlを、蓋部11に設置された不織布に滴下し、尿中の8-OHdGを計測した。コントロールには吸入香料を投与しなかった。
ICRマウスを5匹ずつ以下の各群に分け、比較実験を行った。
・第1群:コントロール(吸入香料を投与せず、放射線も照射しない。)
・第2群:コントロールに0.5Gyの放射線を1回だけ照射する。
・第3群:吸入香料を投与し、放射線は照射しない。
・第4群:吸入香料を投与し、0.5Gyの放射線を1回だけ照射する。
投与群には毎日吸入香料200μlを、蓋部11に設置された不織布に滴下して自然吸入により投与した。コントロールには吸入香料を投与しなかった。
ICRマウスを5匹ずつコントロールと投与群に分けた。投与群には毎日吸入香料200μlを、蓋部11に設置された不織布に滴下して自然吸入により投与した。コントロールには吸入香料を投与しなかった。そして、各群について飲水量の経時変化を比較した。
ICRマウスを5匹ずつコントロールと投与群に分けた。投与群には水で5倍希釈した吸入香料1mlを3週目までは毎日、その後週に3回、投与群のマウスが収容される飼育ケージの床敷きに散布し、自然呼吸させることにより吸入香料を摂取させた。コントロールには水1mlを3週目までは毎日、その後週に3回、コントロールのマウスが収容される飼育ケージの床敷きに散布した。そして、1日当たりの尿中の8-OHdGの量(クレアチニン1mgに対する8-OHdGの量(ng))を実験1と同様の手順にて測定した。
C57BLマウスを4~10匹ずつコントロールと投与群に分けた。そして、各群をさらに以下の3つのグループに分けた。
(1)放射線を照射しないグループ
(2)0.5Gyの放射線を1回だけ全身に照射したグループ
(3)0.75Gyの放射線を1回だけ全身に照射したグループ
放射線の照射は、実験2と同様の方法により行った。
C57BLマウスを4~10匹ずつコントロールと投与群に分けた。そして、各群をさらに以下の2つのグループに分けた。
(1)放射線を照射しないグループ
(2)0.75Gyの放射線を1回だけ全身に照射したグループ
放射線の照射は、実験2と同様の方法により行った。
以上の実験結果により、吸入香料は吸入により摂取された場合、老化による酸化に対する抗酸化作用と、放射線照射ストレスに対する抗酸化作用と、を有することが分かった。また、吸入香料は、夾雑物や他の香料を含有していても効果があることが分かった。さらに、吸入香料が吸入された場合、抗精神ストレス作用があることが分かった。
11 蓋部
12 主室
15 網
Claims (6)
- 液体の吸入香料であって、
青葉アルコールと、
リナロールと、
を含み、エタノールを主溶媒とする吸入香料。 - 前記青葉アルコールは、
全量に対して0.02質量%以上0.5質量%以下であり、
前記リナロールは、
全量に対して0.005質量%以上0.1質量%以下である請求項1に記載の吸入香料。 - 酸化ストレスに対する抗酸化作用を呈する請求項1又は請求項2に記載の吸入香料。
- 抗精神ストレス作用を呈する請求項1から請求項3までのいずれか1項に記載の吸入香料。
- 請求項1から請求項4までのいずれか1項に記載の吸入香料を含み、常温において液体の香水。
- 請求項1から請求項4までのいずれか1項に記載の吸入香料を含み、常温において液体の食品香料。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2016327484A AU2016327484B2 (en) | 2015-09-25 | 2016-07-05 | Inhaling fragrance, perfume, and food flavoring |
AU2019200397A AU2019200397B2 (en) | 2015-09-25 | 2019-01-21 | Inhaling fragrance, perfume, and food flavoring |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-187566 | 2015-09-25 | ||
JP2015187566A JP2018184346A (ja) | 2015-09-25 | 2015-09-25 | 吸入香料、香水、及び食品香料 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017051585A1 true WO2017051585A1 (ja) | 2017-03-30 |
Family
ID=58385999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/069931 WO2017051585A1 (ja) | 2015-09-25 | 2016-07-05 | 吸入香料、香水、及び食品香料 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2018184346A (ja) |
AU (2) | AU2016327484B2 (ja) |
WO (1) | WO2017051585A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022071580A1 (ja) * | 2020-10-01 | 2022-04-07 | 国立大学法人群馬大学 | 2,2,6,6-テトラメチル-1-ピペリジニルオキシルの揮発使用による細胞死抑制と組織保護 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006075112A (ja) * | 2004-09-10 | 2006-03-23 | T Hasegawa Co Ltd | 茶類エキス及び茶類香料の製法 |
JP2012139215A (ja) * | 2010-12-14 | 2012-07-26 | Fukujuen:Kk | 製茶プロセスまたは製茶加工プロセスにおける茶葉香気成分の回収方法、および前記方法により回収された茶葉香気成分を用いた茶飲料の製造方法 |
JP2015109832A (ja) * | 2013-11-05 | 2015-06-18 | 株式会社アクト・フォ | 茶葉芳香蒸留物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05230496A (ja) * | 1992-02-24 | 1993-09-07 | Nippon Fine Chem Co Ltd | 調合香料及び該調合香料を含有する芳香性組成物 |
JPH08113522A (ja) * | 1994-10-14 | 1996-05-07 | Earth Chem Corp Ltd | 加熱蒸散用香料可溶化剤及び加熱蒸散用水性香料組成物 |
JPH08319477A (ja) * | 1995-05-27 | 1996-12-03 | Akio Usui | 発熱体組成物の発熱反応制御方法、発熱体組成物、発熱体、貼付剤、香料放散装置、殺虫剤放散装置又は殺菌剤放散装置 |
WO2002053151A1 (fr) * | 2001-08-08 | 2002-07-11 | Shiseido Company, Ltd. | Compositions parfumantes |
-
2015
- 2015-09-25 JP JP2015187566A patent/JP2018184346A/ja active Pending
-
2016
- 2016-07-05 WO PCT/JP2016/069931 patent/WO2017051585A1/ja active Application Filing
- 2016-07-05 AU AU2016327484A patent/AU2016327484B2/en not_active Ceased
-
2019
- 2019-01-21 AU AU2019200397A patent/AU2019200397B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006075112A (ja) * | 2004-09-10 | 2006-03-23 | T Hasegawa Co Ltd | 茶類エキス及び茶類香料の製法 |
JP2012139215A (ja) * | 2010-12-14 | 2012-07-26 | Fukujuen:Kk | 製茶プロセスまたは製茶加工プロセスにおける茶葉香気成分の回収方法、および前記方法により回収された茶葉香気成分を用いた茶飲料の製造方法 |
JP2015109832A (ja) * | 2013-11-05 | 2015-06-18 | 株式会社アクト・フォ | 茶葉芳香蒸留物 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022071580A1 (ja) * | 2020-10-01 | 2022-04-07 | 国立大学法人群馬大学 | 2,2,6,6-テトラメチル-1-ピペリジニルオキシルの揮発使用による細胞死抑制と組織保護 |
Also Published As
Publication number | Publication date |
---|---|
AU2016327484B2 (en) | 2018-12-06 |
JP2018184346A (ja) | 2018-11-22 |
AU2016327484A1 (en) | 2018-05-10 |
AU2019200397B2 (en) | 2019-08-22 |
AU2019200397A1 (en) | 2019-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1941870B1 (en) | Perfume Composition comprising perilla aldehyde | |
JP4675903B2 (ja) | 脳機能改善効果を有するトリテルペン化合物 | |
Thakur et al. | Antidepressant-like effects of Brassica juncea L. leaves in diabetic rodents | |
Ben Salem et al. | Pharmacological Activities of O lea europaea Leaves | |
CN105920476B (zh) | 防治阿尔茨海默病中药组合物及其制备方法 | |
Murbach et al. | A toxicological safety assessment of a standardized extract of Sceletium tortuosum (Zembrin®) in rats | |
JP6444583B2 (ja) | 経口組成物 | |
JP2009173585A (ja) | 鎮静効果付与剤、鎮静香料組成物、鎮静効果を有する香粧品及び飲食品 | |
Brunetti et al. | IDN 5082, a standardized extract of Salvia miltiorrhiza, delays acquisition of alcohol drinking behavior in rats | |
WO2017051585A1 (ja) | 吸入香料、香水、及び食品香料 | |
JP2008247894A (ja) | ストレス応答力改善剤 | |
CN102860940A (zh) | 除皱护理复方精油 | |
JP2006241051A (ja) | 抗ストレス剤 | |
JP5851398B2 (ja) | 交感神経抑制剤 | |
JP5992305B2 (ja) | 経口体臭改善用組成物 | |
JP5992304B2 (ja) | 経口体臭改善組成物 | |
JP5783552B2 (ja) | 体脂肪低減剤及び体脂肪低減食品 | |
JP5992307B2 (ja) | 経口体臭改善用組成物 | |
Fang et al. | Neuroprotective effect of whole-plant extract of Torilis leptophylla in isoflurane-treated rats | |
JP2009280573A (ja) | 内服用体臭抑制剤 | |
JP2022169855A (ja) | 頻尿改善剤 | |
JP5980512B2 (ja) | 体臭抑制剤 | |
JP5992309B2 (ja) | 経口体臭改善用組成物 | |
Tiwari et al. | Evaluation of diuretic potential of drakshasava prepared by traditional and modern methods in experimental albino rats | |
TWI503123B (zh) | 水丁香萃取物於製備增強記憶功能及延緩神經退化之組合物之用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16848375 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2016327484 Country of ref document: AU Date of ref document: 20160705 Kind code of ref document: A |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 04.07.2018) |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16848375 Country of ref document: EP Kind code of ref document: A1 |